Patents by Inventor Vijay K. Chaudhary

Vijay K. Chaudhary has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Target-specific, cytotoxic, recombinant pseudomonas exotoxin
    Patent number: 5705163
    Abstract: A target-specific, cytotoxic, recombinant Pseudomonas exotoxin is described. Such toxins are made by inserting specific recognition molecules at specific cloning sites in at least domain III near the carboxyl terminus of the PE molecule. Various modifications of the carboxyl terminus of the PE molecule to increase cytotoxicity are set forth. Multifunctional, recombinant, cytotoxic fusion proteins containing at least two different recognition molecules are provided for killing cells expressing receptors to which the recognition molecules bind with specificity. Methods for producing novel recombinant PE molecules with specific properties are described.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 6, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services, National Institutes of Health
    Inventors: Ira Pastan, Vijay K. Chaudhary, David Fitzgerald
  • Psuedomonas exotoxins of low animal toxicity and high cytocidal activity
    Patent number: 5705156
    Abstract: Improved Pseudomonas exotoxins of low animal toxicity and high cytocidal activity are described. Substitution of positively charged amino acid residues with an amino acid residue without a positive charge provides markedly changed exotoxins. Conjugation of the new exotoxins with suitable targeting agents provides cytocidal specificity for killing desired cellular entities.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 6, 1998
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Ira Pastan, David Fitzgerald, Vijay K. Chaudhary
  • Cytotoxic agent against specific virus infection
    Patent number: 5587455
    Abstract: A chimeric gene directing the synthesis of hybrid recombinant fusion protein in a suitable expression vector has been constructed. The fusion protein possesses the property of selective cytotoxicity against specific virus-infected cells. A CD4(178)-PE40 hybrid fusion protein has been made for selectively killing HIV-infected cells.
    Type: Grant
    Filed: November 8, 1994
    Date of Patent: December 24, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Edward A. Berger, Bernard Moss, Thomas R. Fuerst, Ira Pastan, David Fitzgerald, Tamio Mizukami, Vijay K. Chaudhary
  • Pseudomonas exotoxins (PE) and conjugates thereof having lower animal toxicity with high cytocidal activity through substitution of positively charged amino acids
    Patent number: 5512658
    Abstract: Improved Pseudomonas exotoxins of low animal toxicity and high cytocidal activity are described. Substitution of positively charged amino acid residues with an amino acid residue without a positive charge provides markedly changed exotoxins. Conjugation of the new exotoxins with suitable targeting agents provides cytocidal specificity for killing desired cellular entities.
    Type: Grant
    Filed: October 1, 1993
    Date of Patent: April 30, 1996
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Ira Pastan, David Fitzgerald, Vijay K. Chaudhary
  • P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
    Patent number: 5458878
    Abstract: A target-specific, cytotoxic, recombinant Pseudomonas exotoxin is described. Such toxins are made by inserting specific recognition molecules at specific cloning sites in at least domain III near the carboxyl terminus of the PE molecule. Various modifications of the carboxyl terminus of the PE molecule to increase cytotoxicity are set forth. Multifunctional, recombinant, cytotoxic fusion proteins containing at least two different recognition molecules are provided for killing cells expressing receptors to which the recognition molecules bind with specificity. Methods for producing novel recombinant PE molecules with specific properties are described.
    Type: Grant
    Filed: May 14, 1990
    Date of Patent: October 17, 1995
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Ira Pastan, Vijay K. Chaudhary, David Fitzgerald
  • Cytotoxic agent against specific virus infection
    Patent number: 5428143
    Abstract: A chimeric gene directing the synthesis of hybrid recombinant fusion protein in a suitable expression vector has been constructed. The fusion protein possesses the property of selective cytotoxicity against specific virus-infected cells. A CD4(178)-PE40 hybrid fusion protein has been made for selectively killing HIV-infected cells.
    Type: Grant
    Filed: February 25, 1993
    Date of Patent: June 27, 1995
    Assignee: United States of America
    Inventors: Edward A. Berger, Bernard Moss, Thomas R. Fuerst, Ira Pastan, David Fitzgerald, Tamio Mizukami, Vijay K. Chaudhary
  • CD-4/cytotoxic gene fusions
    Patent number: 5206353
    Abstract: A chimeric gene directing the synthesis of hybrid recombinant fusion protein in a suitable expression vector has been constructed. The fusion protein possesses the property of selective cytotoxicity against specific virus-infected cells. A CD4(178)-PE40 hybrid fusion protein has been made for selectively killing HIV-infected cells.
    Type: Grant
    Filed: July 22, 1988
    Date of Patent: April 27, 1993
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Edward A. Berger, Bernard Moss, Thomas R. Fuerst, Ira Pastan, David Fitzgerald, Tamio Mizukami, Vijay K. Chaudhary